Definium Therapeutics, Inc.
DFTX- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001813814
In the last 90 days, Definium Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 362 institutions reported holding it in 13F filings for Q2 2026, worth $5.35B in total; Duquesne Family Office is the only superinvestor holding it.
Q1 2023 vs. Q4 2022
How the institutions holding Definium Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Of which not filed for Q1 2023 | Q1 2023 | Change |
|---|---|---|---|---|
| Holders | 104 | 5 | 89 | −10 |
| Shares | 5.06M | 96.1K | 3.94M | −1.02M (−20.6%) |
| Value | $11.1M | $211.3K | $12.6M | +$1.63M (+14.9%) |
5 institutions that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (9)
Institutions that held Definium Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 55,786 | $177.0K | 0.00% |
| Man Group plc | – | $59.0K | 0.00% |
| Farther Finance Advisors, LLC | 100 | $317 | 0.00% |
| US Bancorp | 66 | $209 | 0.00% |
| Chesapeake Asset Management LLC | 33 | $104 | 0.00% |
| Strategic Investment Solutions, Inc. | 6 | $19 | 0.00% |
| Grey Fox Wealth Advisors, LLC | 6 | $19 | 0.00% |
| Ogorek Anthony Joseph | 16 | $0 | 0.00% |
| VitalStone Financial, LLC | 350 | $0 | 0.00% |
Sold out (19)
Institutions that held Definium Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Merit Financial Group, LLC | 540,287 | $1.19M |
| Millennium Management LLC | 249,450 | $549.0K |
| Virtu Financial LLC | 70,157 | $154.0K |
| Cubist Systematic Strategies, LLC | 61,769 | $135.9K |
| Fore Capital, LLC | 47,999 | $105.6K |
| Occudo Quantitative Strategies LP | 41,864 | $92.1K |
| Aristides Capital LLC | 37,625 | $82.8K |
| Two Sigma Securities, LLC | 24,099 | $53.0K |
| Exchange Traded Concepts, LLC | 14,955 | $32.9K |
| Schonfeld Strategic Advisors LLC | 10,400 | $22.9K |
| Engineers Gate Manager LP | 10,076 | $22.2K |
| Simplex Trading, LLC | 1,374 | $3.00K |
| Legal & General Group Plc | 1,025 | $2.25K |
| Accurate Wealth Management, LLC | 649 | $1.80K |
| Money Concepts Capital Corp | 500 | $1.10K |
| Citigroup Inc | 36 | $79 |
| Rockefeller Capital Management L.P. | 148 | $0 |
| Sierra Capital LLC | 1 | $0 |
| CarsonAllaria Wealth Management, Ltd. | 3 | $0 |
Not filed for Q1 2023 yet (5)
Institutions that held Definium Therapeutics, Inc. at the end of Q4 2022 and haven't filed a 13F for Q1 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Telemetry Investments, L.L.C. | 96,000 | $211.0K |
| Burleson & Company, LLC | 86 | $189 |
| Heritage Wealth Management, LLC | 26 | $57 |
| CoreCap Advisors, LLC | 17 | $37 |
| Sargent Bickham Lagudis LLC | 10 | $22 |